The­seus Phar­ma­ceu­ti­cals lays off most work­ers and seeks 's­trate­gic al­ter­na­tives' af­ter can­cer pipeline fail­ure

The­seus Phar­ma­ceu­ti­cals said af­ter Mon­day’s clos­ing bell that it will let go of 72% of its work­force, or about 26 peo­ple, and will seek “strate­gic al­ter­na­tives” that could in­clude a sale of it­self or its as­sets.

The job cuts come four months af­ter the Cam­bridge, MA-based com­pa­ny scrapped its KIT in­hibitor due to safe­ty con­cerns. Those on the way out in­clude R&D leader William Shake­speare, who will con­sult with the com­pa­ny un­til the end of next June, The­seus said in a press re­lease. More de­tails were in­clud­ed in an SEC fil­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER